Rexahn issued a press release last May announcing positive results of the phase II study of Zoraxel in erectile dysfunction. This is what the company said at that time:
"The study, which was designed to assess Zoraxel's safety and preliminary efficacy in male subjects ages 18 to 65 with ED, demonstrated a dose dependent treatment effect achieved by Zoraxel as assessed by the IIEF survey. Zoraxel was found to be safe and well tolerated, with no serious adverse events reported. Furthermore, subjects treated with Zoraxel demonstrated improved erectile function and significant improvement in the quality of life measures. Planning is underway for the Phase IIb trial, which will include the Sexual Encounter Profile (SEP) survey, IIEF and quality of life study endpoints."
It's been almost a year since Rexahn dropped that announcement, so what's taking so long for the company to provide the actual data from the study? Like with Serdaxin, Rexahn seems to prefer press releases over scientific publication or presentation at medical meetings.
A look at the Zoraxel study on ClinicalTrials.gov shows the phase II study enrolled 40 patients, randomized to one of three doses of Zoraxel (5 mg, 10 mg and 15 mg) or a placebo. The primary endpoints are scores on the International Index of Erectile Function (IIEF) and the Sexual Encounter Profile (SEP) -- both standard measures used in studies to assess erectile dysfunction.
Mark T. writes, "Thank you for all your wonderful insight into Cell Therapeutics (CTIC). I was able to make some money on this stock because of your input. On another note, I am invested now in Celldex Therapeutics (CLDX). Have you ever written about them? Can you provide us with some of your insight here? Is it the next Dendreon (DNDN)?" Celldex's lead drug, CDX-110, is a cancer immunotherapy (so, a cancer "vaccine" cousin to Dendreon's Provenge) targeting glioblastoma multiforme (GBM) aka brain tumors as its lead indication. The data, to date, has been very promising albeit from small, uncontrolled studies, with median overall survival going out to 23-24 months. CDX-110 is partnered with Pfizer (PFE), which refers to the drug as PF-04948568.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV